NPM1 による新たな遺伝子発現制御機構 by Abe Mayumi & 阿部 真弓
A novel gene expression mechanism by NPM1
著者 Abe Mayumi
year 2018
その他のタイトル NPM1 による新たな遺伝子発現制御機構
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2017
報告番号 12102甲第8746号
URL http://doi.org/10.15068/00152255
  
A novel gene expression mechanism by NPM1 
(NPM1 による新たな遺伝子発現制御機構) 
 
 
 
 
 
2017 
Ph.D. Program in Human Biology, 
School of the Integrative and Global Majors, 
University of Tsukuba 
 
Mayumi Abe 
 
 
 1 
Preface 
My scientific interest is how gene expression is regulated in the cells. Since 
chromatin structure affects the binding of trans-acting factors to DNA thereby 
regulates gene expression, it is important to understand the regulation 
mechanism of chromatin dynamics. Histones, which are main components of 
chromatin, have been implicated in the regulator of its dynamics. Histone 
modifications and histone variants can change the interaction between DNA and 
histones. In addition, chromatin remodeling factors such as histone chaperones 
also participate in assembly and disassembly of histones. My laboratory 
previously identified NPM1/nucleophosmin/B23 as a factor stimulating adenovirus 
chromatin remodeling and studied its functions and characteristics by biochemical 
analysis. Recently, we also showed that NPM1 is involved in the regulation of 
various genes. However, the function of NPM1 in the transcription is not well 
understood. The transcriptional regulatory functions of NPM1 are suggested to be 
distinct from the chromatin regulatory functions of NPM1. Therefore, I am 
interested in the mechanism by which NPM1 participates in the regulation of gene 
expression. Importantly, NPM1 is closely related to cancer development. 
Abnormal NPM1 gene expression pattern was often found in cancer cells. About 
30% of acute myeloid leukemia has a mutation in NPM1. In addition, it is known 
that NPM1 is overexpressed in human solid tumors. It is interesting how 
deregulated NPM1 gene expression leads to cancer development. In this 
dissertation, I focused on the function of NPM1 in the transcriptional regulation of 
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the genes, especially the IFN-γ induced genes. These data are described in the 
Chapters 1 and 2. I also discussed the connection between the role of NPM1 in 
transcription and cancer development. In parallel, I also engaged in studying 
about linker histone H1 variants. As I mentioned above, chromatin dynamics is 
quite important for the regulation of gene expression. Linker histone H1 is one of 
the major components of chromatin and involved in the formation of higher order 
chromatin structure. Linker histone H1 has seven variants expressed in somatic 
cells. However, the function of individual H1 variants remains poorly understood. 
To understand the functional difference of H1 variants, I biochemically 
characterized the individual H1 variants. This data is described in Chapter 3. 
Additionally, I also focused on the regulation mechanism maintaining the amount 
of H1. Interestingly, knockout of one H1 variant gene did not affect the total 
amount of H1 that is compensated by the other H1 variants. It is probably because 
of the backup system to maintain the chromatin structure. To understand this 
backup system, I tried to examine the mechanism by which the amount of H1 is 
sensed and regulated. To learn the techniques to analyze the level of individual 
H1 variants, I visited Florida State University. All these achievements about linker 
histone H1 are described in Chapter 4.  
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Chapter 1: Nucleophosmin1/B23 
Nucleophosmin (NPM)/B23 that is also called numatrin [1] or NO38 [2], was 
originally identified as a nucleolar phosphoprotein expressed at higher levels in 
Novikoff-Hepatoma cells compared to normal Rat lever cells [3,4]. The name of 
B23 is derived from a spot number of two dimensional gel electrophoresis. NPM1 
is a member of Nucleophosmin/nucleoplasmin (NPM) family, which is also known 
as histone chaperones family. There are three NPM family proteins termed NPM1, 
NPM2 and NPM3 in mammals (Figure 1). NPM family has a conserved N-terminal 
oligomerization domain and acidic domains that are required for histone 
chaperone activity. The C-terminal domain of NPM1 is essential for RNA binding 
and nucleolar localization [5]. It is also reported that this domain interacts with 
G-rich quadruplex forming DNA [6,7]. The N-terminal core domain contains two 
nuclear export signals (NES), which are recognized by CRM1. NPM1 is mainly 
localized in nucleolar, but it also shuttles between nucleus, nucleoplasm and 
cytoplasm [8]. This shuttling is regulated by these two NES and a nuclear 
localization signal (NLS), which is present between two acidic regions [9]. In 
addition to NPM1/B23.1, two splicing variants have been identified namely B23.2 
and B23.3. The last 25 C-terminal amino acids of NPM1/B23.1 are absent in 
B23.2, whereas B23.3 lacks 29 amino acids of B23.1 at the C-terminal basic 
amino acid rich region (Figure 1). NPM1 forms a pentamer and decamer through 
N-terminal oligomerization domain [10,11]. Disruption of NPM1 oligomerization 
causes nucleoplasmic localization [12,13], suggesting that oligomerization is 
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required for nucleolar localization.  
At present, many studies have reported the multiple functions of NPM1. One 
main feature of NPM1 is to function as histone chaperone. Previously, our 
laboratory identified NPM1 as a major component of template activating factor-III, 
which can stimulate adenovirus core DNA replication mediated by chromatin 
remodeling activity [14]. In addition, we reported that NPM1 binds to core histones, 
preferentially to histone H3, and acts as histone chaperone [15]. NPM1 also	 
shows a chaperone activity for linker histone H1 [16].  
Importantly, NPM1 is involved in the multiple steps of ribosome biogenesis. 
NPM1 is directly interacted with ribosomal protein L5, which is a known 
chaperone for the 5S rRNA and transport L5 ribosome complexes from nuclear to 
cytoplasm [17]. It has been reported that NPM1 has intrinsic ribonuclease activity 
for maturing rRNA transcript [18,19]. Previous study by our laboratory 
demonstrated that NPM1 is associated with the rRNA gene chromatin and 
promotes the transcription of rRNA gene [20].  
Furthermore, NPM1 is involved in the processes of DNA replication and 
centrosome duplication. It was reported that NPM1 interacts with retinoblastoma 
protein and synergistically stimulates DNA polymerase alpha activity [21]. NPM1 
has been shown to associate with the unduplicated centrosome and dissociates 
from it after phosphorylation on threonine 199 by CDK2 and cyclin E, which 
enables the centrosome duplication [22]. During mitosis, phosphorylated NPM1 
associates with the centrosome and contributes to correct spindle formation and 
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chromosome segregation [23].  
NPM1 knockout mouse shows the aberrant organogenesis and die between 
embryonic day E11.5 and E16.5 because of the severe anemia resulting from 
defects in primitive haematopoiesis [24]. NPM1 inactivation leads to chromosome 
amplification and genomic instability, which can induce the p53 dependent 
cell-cycle arrest and apoptosis [24].  
It is well known that NPM1 is involved in the tumorigenesis. The NPM1 gene 
is mutated at C-terminal region in about 30% of acute myeloid leukemia, which 
results in the aberrant cytoplasmic expression of NPM1 [25]. NPM1 gene locus is 
frequently targeted in chromosome translocation associated with haematopoietic 
tumors, which results in the expression of oncogenic fusion proteins [26-28]. 
NPM1 is highly expressed in various solid tumors such as gastric, colon, ovarian 
and prostate, thus it has been proposed as a tumor marker [29]. 
NPM1 has been implicated in both growth promoting and growth 
suppression pathways. It was found that ARF promotes ubiquitin-dependent 
degradation of NPM1 and interferes rRNA processing mediated by NPM1 [30]. On 
the other hand, NPM1 interacts with ARF in the nucleolus and inhibits the 
association between ARF and MDM2, which results in the release of MDM2 and 
proteasomal degradation of p53 [31]. In normal cells, ARF is not expressed and 
MDM2 maintains low levels of p53, when oncogenic stimuli induce the expression 
of ARF, which allowing the down-regulation of NPM1 and the releasing ARF into 
the nucleoplasm. It leads to p53 activation and inhibition of cell growth. The 
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overexpression of NPM1 increases the nucleolar localization of ARF [31]. It is 
suggested that the high expression level of NPM1 is linked to increased 
proliferation by interfering the p53 activation by ARF. These observations suggest 
that NPM1 functions as a proto-oncogene. In contrast, other studies reported that 
NPM1 is directly interacted with MDM2 independently of ARF and protect p53 
from proteasome degradation [32]. In this case, it is suggested that NPM1 acts as 
a tumor suppressor gene.  
NPM1 is involved in transcription processes through their interaction with 
transcription factors. NPM1 reduces the transcription activity of YY1 and IRF1 by 
binding to these proteins [33,34]. NPM1 and AP2γ form a complex and act as a 
transcriptional repressor of ERα [35]. It was shown that during retinoic acid 
induced cell differentiation, AP2α recruits NPM1 to the promoters of retinoic acid 
responsive genes and NPM1 acts as a negative co-regulator for their expressions 
through recruitment of histone deacetylases [36]. Meanwhile, NPM1 enhances 
the gene expression of MnSOD by interacting with NFκB [37]. We recently 
reported that NPM1 enhances the DNA binding ability of NFκB and positively 
regulates the NFκB mediated transcription [38]. NPM1 directly interacts with 
c-Myc and regulates the expression of c-Myc target genes at their promoter [39].  
As described above, it has been revealed that NPM1 is involved in many 
critical cellular processes. In this dissertation, I examined the function of NPM1 in 
transcription regulation. I identified the genes regulated by NPM1 and examined 
its regulation mechanism.   
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Figure 1. Schematic representations of the human NPM1 family proteins 
Human NPM1 family members, NPM1, NPM2, and NPM3, are represented. NPM 
family has a conserved N-terminal oligomerization domain and acidic domains. 
NPM1 forms a pentamer and decamer through N-terminal oligomerization domain. 
Only NPM1 has the RNA binding domain at the C-terminal region. The N-terminal 
core domain contains two nuclear export signals (NES). Nuclear localization 
signal (NLS) is present between two acidic regions. Two splicing variants of 
NPM1/B23.1 have been identified namely B23.2 and B23.3. The last 25 
C-terminal amino acids of NPM1/B23.1 are absent in B23.2, whereas B23.3 lacks 
29 amino acids of B23.1 at the C-terminal basic amino acid rich region.   
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Chapter 2: Selective regulation of the type II IFN- 
inducible genes by NPM1/nucleophosmin 
 
2-1. Abstract 
NPM1/nucleophosmin is a multifunctional nucleolar protein. Here, I analyzed 
the function of NPM1 in gene expression using previous our microarray data and 
found a relationship between NPM1 and interferon (IFN)-γ-inducible genes. I 
showed that NPM1 selectively regulates the expression of a subset of 
IFN-γ-inducible genes and directly binds to two important transcription factors in 
the type II IFN pathway: STAT1 and IRF1. Furthermore, NPM1 was found to 
regulate the IFN-γ-inducible promoter activity of MHC class II transactivator 
(CIITA) and mutation of the IRF1 binding site on the CIITA promoter abolished the 
effect of NPM1. My results suggest a novel mechanism for IFN-γ-mediated gene 
expression by NPM1.  
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2-2. Introduction 
NPM1/nucleophosmin is a phosphoprotein that is mainly localized in the 
nucleolus, although it constantly shuttles between the nucleolus, the nucleus, and 
the cytoplasm [8]. Importantly, NPM1 is highly expressed in human solid 
malignancies and has been implicated in tumorigenesis; genetic mutations of its 
gene are frequently found in acute myeloid leukemia [25,40]. Therefore, it is 
important to understand the functions of NPM1 in both normal and malignant cells. 
NPM1 is a multifunctional protein, which is involved in the regulation of ribosome 
biogenesis, DNA replication, apoptosis, centrosome duplication, and cell 
proliferation [29,40]. We previously reported that NPM1 shows histone chaperone 
activity in vitro and participates in the regulation of chromatin structure [15]. It has 
been also shown that NPM1 interacts with transcription factors including c-Myc, 
NFκB, YY1, AP-2γ, and IRF1, and is required for the regulation of their target 
genes [33-35,38,39]. Consistent with these observations, our recent microarray 
analysis demonstrated that NPM1 is involved in the regulation of various genes 
[38]; however, the molecular mechanism by which NPM1 regulates the 
expression of those genes is not well understood. 
Interferons (IFNs) are cytokines that play important roles in antiviral and 
anti-proliferative responses [41]. IFNs are classified into type I, II, and III based on 
receptor specificity and sequence homology. 
The main signaling pathway activated by IFNs is the Janus-activated kinase 
(JAK) signal transducer and activator of transcription (STAT) pathway [41,42]. 
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Type I and II IFNs bind the IFN-α receptor (IFNAR) and the IFN γ receptor 
(IFNGR), respectively. The binding of type I IFNs to IFNAR results in the 
autophosphorylation and activation of the receptor-associated JAK1 and tyrosine 
kinase 2 (TYK2) pathways, which in turn regulates the tyrosine phosphorylation of 
STAT1 and STAT2. Tyrosine-phosphorylated STAT1 and STAT2 heterodimers 
translocate to the nucleus, where they assemble with IFN-regulatory factor 9 
(IRF9) to form a complex called IFN-stimulated gene factor 3 (ISGF3). This 
complex binds to specific elements, termed IFN stimulated response elements 
(ISREs) that are present in the promoters of IFN-stimulated genes (ISGs) to 
initiate transcription. The type III IFNs bind to a receptor complex composed of 
interferon lambda receptor 1 (IFNLR1) and interleukin-10 receptor B (IL10RB), 
and use the JAK-STAT signal transduction pathway similarly to type I IFNs [43]. 
 In contrast, the only type II IFN, IFN-γ, binds to the IFN-γ receptor, followed 
by JAK1- and JAK2-mediated phosphorylation of STAT1. Phosphorylated STAT1 
homodimers, translocate to the nucleus, and bind to the DNA sequence termed 
the IFN-γ activation site (GAS) to initiate transcription.  
Interferon regulatory factor 1 (IRF1) is induced by both IFN-α/β and IFN-γ 
and binds to the ISRE/IRF-E sequence on the target genes’ promoters. The major 
histocompatibility complex (MHC) I and II genes, which are required for antigen 
presentation, are induced by IRF1 on stimulation with IFN-γ [44]. The NOD-like 
receptor family CARD domain containing 5 (NLRC5), and MHC class II 
transactivator (CIITA) genes are also required for the expression of MHC I and 
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MHC II genes, respectively [45-47].  
From the previous microarray data, I found that the expression of 
IFN-γ-inducible genes is decreased by NPM1 knockdown. Interestingly, I 
demonstrated that NPM1 binds directly to both STAT1 and IRF1, and participated 
in the transcriptional regulation of a subset of IFN -γ-inducible genes. I propose a 
novel mechanism for the type II IFN signaling pathway by NPM1. 
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2-3. Materials and methods 
2-3-1. Plasmid construction 
Plasmids pGEX2T-NPM1, pET14b-NPM1, pET14b-B23.2, pET14b-B23.3, 
pET14b-NPM1ΔA, pET14b-NPM1ΔC, pET14-NPM1ΔN, pET14b-NPM1CR, and 
pET14b-NPM1CR1.5 were described previously [48]. The STAT1 and IRF1 were 
amplified by PCR using primer sets 5’- aaaggatccatgtctcagtggtacgaact-3’ and 
5’-aaaggatccctatactgtgttcatcatac-3’, and 5’-agctggatccatgcccatcactcggatgcg-3’ 
and 5’-agcgaattctacggtgcacagggaatggcc-3’ with cDNA prepared from HeLa cells 
as a template. The amplified cDNAs were subcloned into BamH I and EcoR I sites 
of pcDNA3.1-Flag vector. To construct pCAGGS-Flag-IRF1, the IRF1 cDNA was 
cut out from pcDNA3.1-Flag-IRF1 by Hind III and EcoR I, blunted by Klenow 
Fragment (Toyobo), and subcloned into pCAGGS treated with Xho I and Klenow 
fragment. To construct pGEX6P-1-IRF1, the IRF1 cDNA was cloned into BamH I 
and EcoR I sites of pGEX6P-1 vector. The promoter IV sequence of the human 
CIITA gene (CIITA-237) was amplified by PCR using a primer set 5’- 
AAAAGATCTGGGGCCTGGGACTCTCCCCG-3’ and 5’- 
AAAAAGCTTCCCGACCTTAGGGGTTACAG-3’ with genomic DNA extracted 
from HeLa cells as a template. To construct a series of 5’ deletion mutants, 
forward primers 5’- AAAAGATCTTTGGGATGCCACTTCTGATA-3’ for CIITA-154, 
5’-AAAAGATCTCAGCGCTGCAGAAAGAAAGT-3’ for CIITA-82, or 5’- 
AAAAGATCTGAAAAAGAACTGCGGGGAGG-3’ for CIITA-54 and the reverse 
primer described above were used. The amplified DNA was subcloned into Bgl II 
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and Hind III sites of pGV-B vector. Site directed mutations at the IRF1 recognition 
sequence and the GAS in pGV-B-CIITA-237 were introduced by primer sets 5’- 
CTTTTTCTCGAGCACTGTCTTTCTGCAGCGCTGAGCTCG-3’ and 5’- 
GCAGAAAGACAGTGCTCGAGAAAAAGAACTGCGGGGAGG-3’, and 
5’-CACGTGCTTTAGAATTCGTGGCATCCCAACTGCCTGG-3’ and 
5’-ATGCCACGAATTCTAAAGCACGTGGTGGCCACAGTAG-3’, respectively. 
2-3-2. Cell culture, transfection and reagents 
HeLa and 293T cells were maintained in Dulbecco’s modified Eagle’s medium 
(Nacalai Tesque) supplemented with 10% heat-inactivated fetal bovine serum at 
37oC with 5% CO2. The stable cell line of HeLa cells with pEGFP-Flag-NPM1 was 
established previously [49] and maintained as described above.  
Transient transfection of plasmid DNA and siRNAs were performed using 
GeneJuice (Novagen) and Lipofectamine RNA iMAX (Life Technologies), 
respectively, according to the manufacturer’s instructions. Stealth RNAs for 
negative controls and human NPM1 were described previously [49]. Antibodies 
used were NPM1 (Invitrogen), Flag-tag (M2, Sigma Aldrich), STAT1 (sc-346, 
Santa Cruz), p-STAT1 (Y701) (D4A7, CST), IRF1 (ab26109, Abcam), and β-actin 
(sc-47778, Santa Cruz). Recombinant human IFN-β and IFN-γ (PEPROTECH) 
were commercially available. 
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2-3-3. Purification of recombinant proteins 
For expression and purification of GST tagged proteins, BL21 (DE3) and BL21 
(RIL) were transformed with pGEX2T-NPM1 and pGEX6P-1-IRF1, respectively. 
The transformed E.coli was grown at 37oC until OD600 reached 0.4. Expression 
of the recombinant proteins was induced by the addition of isopropyl 
β-D-thiogalactopyranoside at 16oC for 16 h. Bacterial cell lysates expressing 
GST-tagged proteins were sonicated in buffer A (50 mM Tris-HCl (pH 7.9), 0.1% 
Triton X-100, and 1 mM phenylmethylsulfonyl fluoride (PMSF)) containing 100 
mM NaCl. For purification of Flag-tagged STAT1, 293T cells transfected with 
pcDNA3.1-Flag-STAT1 were suspended in buffer B (0.2% Triton X-100, 20 mM 
Tris-HCl pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM PMSF) containing 400 mM 
NaCl on ice for 10 min and rotate at 4oC for 30 min followed by centrifuge at 
21,500 x g, 4oC for 15 min. The supernatants were recovered and diluted with 
twice volumes of buffer B without NaCl. The cell extracts were incubated with 
anti-Flag M2 affinity gels (Sigma Aldrich) for 2 h at 4oC and then washed by buffer 
A containing 300 mM NaCl. The proteins bound with the resin were eluted with 
buffer A containing 150 mM NaCl and Flag peptide (Sigma Aldrich), and the 
eluted proteins were dialyzed against buffer H (20 mM Hepes-NaOH pH7.9, 50 
mM NaCl, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol 
(DTT), 0.5 mM PMSF and 10% glycerol). Purification of His-tagged proteins were 
described previously [48].  
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2-3-4. Immunoprecipitation and GST-pull down assays 
Flag-IRF1 was transiently expressed in 293T cells. The cells were treated with or 
without IFN-γ for 6 h, collected, and sonicated in buffer A containing 100 mM NaCl. 
The cell lysates were incubated with anti-Flag M2 affinity gels (Sigma Aldrich) in 
buffer A containing 100 mM NaCl. The resins were washed extensively with the 
same buffer. The proteins bound with the resin were eluted with buffer A 
containing 100 mM NaCl and Flag peptide (Sigma Aldrich), separated by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed 
by western blotting. For immunoprecipitation of STAT1, HeLa cells were treated 
without or with IFN-γ for 1 h and the cell lysates were prepared. The extracts were 
subjected to immunoprecipitation with control IgG or anti-STAT1 antibody, and 
immunoprecipitated proteins were separated by SDS-PAGE and detected by 
western blotting. For GST-pull down assays, glutathione sepharose beads 
immobilized GST, GST-NPM1 or GST-IRF1 were mixed with Flag-STAT1, 
His-NPM1 or its deletion mutants, and incubated at 4oC for 1 h followed by 
extensive washing with buffer A containing 100 mM NaCl. Proteins were eluted 
from the beads by an SDS sample buffer, separated by SDS-PAGE, and 
visualized by CBB staining or western blotting. 
2-3-5. Reporter assay 
HeLa cells (4x104 per well) transfected with control or NPM1 siRNA were seeded 
in 24-well plates and transfected with 125 ng of pGV-B-CIITA, pGAS-TA-Luc 
(Clontech), or pISRE-TA-Luc (Clontech) (Firefly luciferase) and 125 ng of pTA-RL 
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(Renilla luciferase) 24 h after siRNA transfection. Twenty-four hours after plasmid 
DNA transfection, cells were treated with IFN-γ (20 ng/ml) for 24 h. For 
pISRE-TA-Luc reporter, cells were treated with IFN-β (1000 IU/ml) for 3h. 
Luciferase assay was performed using Renilla Luciferase Assay System kit 
(Promega Corporation, USA) according to the manufacturer’s instructions. 
2-3-6. RT-qPCR 
HeLa cells were transfected with siRNA for NPM1 or negative control for 48 h and 
IFN-γ (20 ng/ml) was added and further incubated for 24 h. Total RNA was 
extracted using RNeasy Kit (Qiagen) according to the manufacturer’s instructions. 
cDNA was prepared from purified RNA (1 µg) by using ReverTraAce (Toyobo) 
with oligo dT primer. Real-time PCR was carried out in triplicate with SYBR Green 
Real time PCR Master Mix-Plus (Toyobo) in the Thermal Cycler Dice Real-Time 
PCR system (TaKaRa). Primer sets for RT-PCR are listed in table, 2-7. 
2-3-7. Immunofluorescence 
The cells on cover slips were fixed with 3% paraformardehyde in PBS, 
permeabilized in a buffer (300 mM sucrose, 3 mM MgCl2 in PBS) containing 0.5% 
Triton X-100, and incubated in PBS containing milk and 0.1% Triton X-100. The 
fixed and permeabilized cells were incubated with anti-STAT1 or IRF1 antibodies 
diluted with PBS containing 0.5% non-fat dry milk. The cells on coverslips were 
washed with PBS containing 0.1% Triton X-100 (PBST), incubated with 
secondary antibodies conjugating with AlexaFluor dyes (Molecular Probes), 
washed extensively with PBST, and incubated with TO-PRO-3 (Invitrogen). All 
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fluorescence images were captured by a confocal microscopy (LSM 5 Exciter, 
Carl Zeiss). 
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2-4. Results 
2-4-1. NPM1 regulates the transcription of IFN-γ-induced genes 
Previously, my laboratory performed a comprehensive microarray analysis 
of the effect of NPM1 knockdown on gene expression in HeLa cells [38], where 
539 genes were found to be downregulated (<0.669-fold). Gene ontology analysis 
of these genes showed functional enrichment in immune responses including 
antigen processing and presentation via MHC class I (Figure 2-1A). I also noticed 
that the immune response genes decreased by NPM1 knockdown are induced by 
IFN-γ; therefore, I questioned whether NPM1 is involved in the type II IFN 
signaling pathway. I first focused on the genes encoding the class I and II antigen 
presentation machinery. To confirm the microarray results, RT-qPCR was 
performed using HeLa cells treated with control or NPM1 siRNA and IFN-γ 
(Figures 2-1B and C). NPM1 was efficiently reduced by NPM1 siRNA treatment 
(Figure 2-1B). The expression of the human MHC class I gene, HLAB, was 
detected at a low level and that of the MHC class II genes, HLADR and HLADQ, 
was not detected under nonstimulated conditions. The expression of both MHC 
class I and II genes was greatly increased upon IFN-γ treatment. Interestingly, I 
demonstrated that the expression of these MHC genes decreased by NPM1 
knockdown, suggesting that NPM1 is involved in the type II IFN signaling pathway. 
To gain insight into the function of NPM1 in the type II IFN signaling pathway, I 
next focused on the transcription regulators of IFN-γ induced transcription (Figure 
2-1D). It is well-established that STAT1 is a master regulator of the type II IFN 
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signaling pathway and activated-STAT1 induces downstream genes such as IRF1, 
CIITA, NLRC5, and STAT1 itself by binding to the consensus sequence (GAS) in 
their promoters [42,44,50]. These transcription factors induced by STAT1 are 
required for the IFN-γ-induced expression of the MHC genes. Under 
nonstimulated conditions, the expression of CIITA was not detected, indicating 
that CIITA is required for the expression of the MHC II genes in HeLa cells. The 
expression levels of STAT1, IRF1, CIITA, and NLRC5 were increased by IFN-γ 
treatment and those of STAT1, IRF1, and CIITA, but not NLRC5, were 
significantly reduced by NPM1 knockdown. These results raised the possibility 
that NPM1 is selectively involved in the regulation of a subset of STAT1 target 
genes. I also examined whether NPM1 knockdown decreases the protein levels of 
STAT1 and IRF1 by quantitative western blotting (Figure 2-1E) using the level of 
actin as a loading control. Consistent with the RT-qPCR results, the expression of 
the STAT1 protein in NPM1 knockdown cells was lower than that in control cells 
6-24 h after IFN-γ treatment. However, the levels of IRF1 in control and NPM1 
siRNA treated cells were similarly increased after IFN-γ treatment.  
To examine the function of NPM1 in the type II IFN signaling pathway, I next 
examined the localization of NPM1 in cells treated with IFN-γ using HeLa cells 
stably expressing EGFP-tagged NPM1. NPM1 mainly localizes to the nucleoli in 
control cells and shuttles between the nucleoplasm and the nucleoli. On IFN-γ 
treatment, NPM1 localization was not clearly changed, while STAT1 and IRF1 
were clearly accumulated in the nuclei (Figure 2-2A). I also examined the 
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expression of the genes involved in the IFN-γ signaling pathway: IFN-γ receptors 
(IFNGR1 and IFNGR2) and kinases (Jak1 and Jak2) that phosphorylate STAT1 
(Figure 2-2B). The expression of these genes was not clearly induced by IFN-γ 
and NPM1 knockdown did not clearly affect their expression. I next examined the 
STAT1 phosphorylation after IFN-γ treatment in control and NPM1 knockdown 
cells (Figure 2-2C). STAT1 phosphorylation at tyrosine 701 (Y701) was clearly 
detected 15 min after IFN-γ addition in both control and NPM1 knockdown cells. 
Quantitative analysis by western blotting revealed that the level of STAT1 protein 
and its phosphorylation were not significantly affected by NPM1 knockdown 
during or 180 min after IFN-γ treatment, although the level of STAT1 protein in 
NPM1 knockdown cells was slightly lower than in control cells. In addition, STAT1 
was similarly accumulated in the nuclei in both control and NPM1 knockdown cells 
1 h after IFN-γ treatment (Figure 2-2D). In parallel, I showed that accumulation of 
IRF1 in control and NPM1 knockdown cells was not significantly different. These 
results suggest that NPM1 regulates the type II IFN signaling pathway after IRF1 
and STAT1 are translocated to and accumulate in the nucleus.  
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2-4-2. NPM1 affects STAT1-mediated transcription 
Because NPM1 depletion decreased the IFN-γ induced expression of 
STAT1 (see Figure 2-1E), it is likely that NPM1 affects both the type I and II 
interferon signaling pathways. To address this point, I performed reporter assays 
using pGAS-TA-luc and pISRE-TA-luc reporter plasmids (Figures 2-3A and B), 
which contains the binding sites of STAT1 homodimer (gamma associated site, 
GAS) and ISGF3 (IFN-stimulated response element, ISRE), respectively. I 
observed IFN-γ-induced expression of the reporter gene, but not IFN-β-induced 
expression, was significantly reduced by NPM1 knockdown. These results 
suggest that NPM1 is involved in the regulation of the type II IFN signaling 
pathway, and that the decreased type II IFN induced gene expression by NPM1 is 
not simply explained by decreased STAT1 expression. 
     To clarify the mechanism by which NPM1 regulates STAT1-medicated 
transcription, I examined the endogenous interaction between NPM1 and STAT1 
by co-immunoprecipitation with anti-STAT1 antibodies in HeLa cells treated with 
or without IFN-γ (Figure 2-3C). Endogenous NPM1 was co-immunoprecipitated 
with STAT1 independent of IFN-γ treatment. To test whether NPM1 directly 
interacts with STAT1, I prepared recombinant proteins of GST, GST-tagged 
NPM1, and Flag-tagged STAT1 (Figure 2-3D), and GST-pull down assays were 
performed (Figure 2-3E). Flag-tagged STAT1 precipitated with GST-tagged 
NPM1, but not with GST, indicating that NPM1 directly associates with STAT1. 
These results suggest that NPM1 is involved in the type II IFN pathway by direct 
 24 
interaction with STAT1. 
2-4-3. NPM1 regulates the CIITA gene expression 
  Next, I examined whether NPM1 regulates the promoter activity of STAT1 
target genes. To this end, I chose the promoter activity of the CIITA gene, 
because its expression is absolutely dependent on IFN-γ and is significantly 
decreased by NPM1 knockdown in HeLa cells (see Figure 2-1). The expression of 
the CIITA gene is controlled by four different promoters; pI, pII, pIII and pIV [51]. 
CIITA pI and pIII are active in cells of myeloid and lymphoid origins, respectively, 
while the significance of CIITA pII remains unknown [52]. CIITA pIV is induced by 
IFN-γ in most cell types; therefore I focused on this promoter element. The 
proximal promoter region of pIV contains multiple cis-acting elements recognized 
by transcription factors such as NFκB, NF-GMa, STAT1 (GAS), USF1 (E box), 
and IRF1 [53]. To examine the effect of NPM1 on the promoter activity of CIITA 
pIV upon IFN-γ treatment, I prepared the proximal promoter of human CIITA pIV 
with a series of 5’ deletion mutants and performed reporter assays (Figure 2-4A). 
Consistent with the decreased expression of endogenous CIITA in NPM1 
knockdown cells, the reporter activity of the pGV-B-CIITA-237 construct, which 
contains 237 base pairs (bp) upstream and 115 bp downstream of the 
transcription start site (+1) of the CIITA gene was significantly decreased by 
NPM1 knockdown. The reporter activity of the NFκB binding element deletion 
construct (pGV-B-CIITA-154) was similar to that of the full-length construct and 
was decreased by NPM1 depletion, suggesting that NFκB is not involved in the 
 25 
regulation of the CIITA gene under the assay condition employed here. Further 
deletion of three elements, the NF-GMa binding site, GAS, and the E box (pGV-B- 
CIITA-82), partially reduced IFN-γ-induced reporter gene expression, and its 
reporter activity induced by IFN-γ was decreased by NPM1 knockdown. 
Conversely, the deletion construct pGV-B-CIITA-54 abolished IFN-γ-induced 
expression of the reporter gene, and the reporter activity of this construct was not 
affected by NPM1 knockdown.  
To further confirm the result of the CIITA promoter analysis by NPM1 
knockdown, I generated constructs with site-specific mutations either in the GAS 
or IRF1 binding sequences. In accordance with the results of the GAS element 
deletion construct (pGVB CIITA-82), the mutation of GAS slightly decreased the 
IFN-γ induction and IFN-γ-induced expression of this construct was decreased by 
NPM1 knockdown (Figure 2-4B). When the CIITA promoter contained mutations 
at the IRF1 binding site, the IFN-γ induced reporter activity was abolished but also 
not affected by NPM1 knockdown (Figure 2-4C). These results suggest that 
NPM1 regulates the IFN-γ induced stimulation of CIITA pIV via IRF1, although I 
could not completely exclude the possibility that NPM1 regulates STAT1 binding 
to the CIITA pIV.
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2-4-4. NPM1 binds to IRF1 through the oligomerization domain 
Previous study has shown that NPM1 interacts with IRF1 through its 
multifunctional domain 2 in vitro [54]. To confirm this interaction, Flag tagged IRF1 
was expressed in 293T cells and an immunoprecipitation assay performed (Figure 
2-5A). 293T cells were used here to obtain sufficient amounts of Flag-IRF1 for 
immunoprecipitation. I found that Flag-tagged IRF1 binds to endogenous NPM1 in 
the absence or presence of INF-γ treatment. To determine the IRF1 binding 
region of NPM1, GST-pull down assays are carried out with a series of NPM1 
deletion mutant proteins (Figure 2-5B). The two splicing variants of NPM1/B23.1, 
namely B23.2 and B23.3, which lack the C-terminal RNA binding domain and the 
basic region, respectively, interacted with IRF1 (Figure 2-5C), This indicates that 
the C-terminal domain and the basic region are dispensable for the interaction. 
These two highly acidic regions are known requirements for efficient histone 
binding and nucleosome assembly [14]. The deletion of these acidic regions did 
not affect the interaction with IRF1 (Figure 5D, lanes 7–8). Further analyses 
showed that the C-terminal half of the protein (amino acid 121–294) was 
dispensable for IRF1 binding and the N-terminal oligomerization domain (amino 
acid 1–120) was sufficient to interact with IRF1.  
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2-5. Discussion 
In this study, I demonstrated that NPM1 regulates a subset of 
IFN-γ-inducible genes such as the MHC class I and II genes (Figure 2-1C). The 
effect of NPM1 knockdown is likely due to the decreased expression of the 
transcription regulators, STAT1, IRF1, and CIITA (Figure 2-1D), all of which are 
induced by IFN-γ. The STAT1 protein level induced by IFN-γ treatment was also 
decreased by NPM1 knockdown (Figure 2-1E), suggesting that the regulation of 
the STAT1 expression level is a primary function of NPM1 in the type II IFN 
signaling pathway. Given that NPM1 did not affect the phosphorylation of STAT1 
at tyrosine 701 or the nuclear accumulation of STAT1 and IRF1 (Figure 2-2B and 
2-2C), it is suggested that NPM1 regulates the type II IFN signaling pathway after 
the nuclear accumulation of STAT1 and IRF1. Although I demonstrated that 
NPM1 directly binds to STAT1 and regulates the expression of a reporter gene 
containing GAS (Figure 2-3A, C, and E), NPM1 failed to regulate the STAT1 
target gene NLRC5. These results suggest that NPM1 confers a preferential 
binding sequence of STAT1. Sequence variation in GAS or the sequences 
adjacent to GAS may affect the sequence preference of the STAT1-NPM1 
complex. 
In HeLa cells, the expression of the MHC class II gene and its regulator 
CIITA was not detected by RT-PCR. This supports the previous finding that CIITA 
is an essential transcription regulator of the MHC class II genes, but not the MHC 
class I genes. My results imply that NPM1 regulates the expression of the MHC 
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class II genes via decreased expression of the CIITA gene. Although the CIITA 
pIV promoter contains STAT1 binding sites, NPM1 knockdown decreased the 
activity of the CIITA pIV even in the absence of STAT1 binding sites (Figure 2-4A 
and B). It was previously demonstrated that the binding of STAT1 to CIITA pIV 
depends on the transcription factor USF1, which binds to the E box on CIITA pIV 
[53]. This local environment of GAS on CIITA pIV may be why NPM1 does not 
affect STAT1 binding. Thus, it is likely that NPM1 regulates the function of IRF1 in 
IFN-γ-induced expression of CIITA. However, STAT1 did not stimulate CIITA pIV 
activity when the IRF1 binding site was mutated; therefore, I could not exclude the 
possibility that NPM1 regulates the CIITA pIV via interaction with both STAT1 and 
IRF1. 
Consistent with previous studies [34,54], I found that NPM1 shows potential 
association with IRF1 (Figure 2-5). Although a previous study reported that NPM1 
inhibits the DNA binding of IRF1 [34], my results suggest that NPM1 positively 
regulates IRF1 function. Further study is required to address this discrepancy and 
to clarify the molecular mechanism by which NPM1 regulates the IRF1 function.  
Although the effect of NPM1 knockdown on the expression of the reporter 
gene containing ISRE induced by IFN-β was not clearly observed (Figure 2-3B), I 
cannot exclude the possibility that NPM1 regulates the type I IFN-inducible genes 
that contain different ISRE sequences or ISRE adjacent to cis-regulatory 
elements. It is possible that NPM1 associates with and regulates the function of 
ISGF3 through its STAT1 binding activity. 
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     Here, I demonstrated that NPM1, an oncogenic nucleolar protein, is involved 
in the regulation of the type II IFN signaling pathway. INF-γ is a well -established 
proinflammatory cytokine that plays critical roles in both the acquired and innate 
immune systems, host defense, and in tumor surveillance [42]. It also plays a role 
in enhancing the inflammatory responses in damaged sites and tumor 
microenvironments. My coworker previously demonstrated that NPM1 regulates 
the TNF-α inflammatory response by enhancing the DNA binding activity of NFκB 
[38]. These results suggest a key regulatory role of NPM1 in inflammation and 
various diseases including cancer caused and/or enhanced by inflammation 
(Figure 2-6).  
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2-6. Figures and legends 
 
Figure 2-1. NPM1 regulates the transcription of IFN-γ-induced genes. 
(A) Gene ontology analysis of the gene set decreased by NPM1 knockdown. The 
gene ontology analysis was performed using the 539 downregulated genes and 
the list of the enriched functions was shown. The previous microarray data (NCBI 
Gene Expression Omnibus (GEO) under accession number GSE81785) 
was  used. (B) Knockdown of NPM1 by siRNA. Expression of NPM1 in HeLa cells 
treated with control or NPM1 siRNA were examined by western blotting using 
anti-NPM1 antibody. Actin was used as a loading control. (C and D) RT-qPCR 
analyses. Please see next page. 
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Figure 2-1. NPM1 regulates the transcription of IFN-γ induced genes.  
(C and D) RT-qPCR analyses. RNA was extracted from control or NPM1 
knockdown HeLa cells treated without or with IFN-γ (20 ng/ml) for 24 h as 
indicated at the bottom of the graphs and RT-qPCR was performed using 
gene-specific primers. White and black bars indicate the results from control and 
NPM1 siRNA, respectively. Relative mRNA levels were normalized by the 
expression level of GAPDH. Three independent experiments were performed and 
error bars indicate ±SD. The results were statistically analyzed by t-test and ***, **, 
and * represent P < 0.001, 0.01 and 0.05, respectively. (E) Effect of NPM1 
knockdown on the expression level of STAT1 and IRF1. HeLa cells were treated 
with control or NPM1 siRNA for 72 h and IFN-γ (20 ng/ml) was added and further 
incubated for 6, 12, and 24 h. The expression levels of STAT1, IRF1, NPM1, and 
β-actin were examined by western blotting. The band intensities of STAT1, IRF1, 
and β-actin were measured and those of STAT1 and IRF1 were normalized by the 
intensity of β-actin. Three independent experiments were performed and error 
bars indicate ±SD. 
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Figure 2-2. NPM1 does not affect the early steps of IFN-γ signaling pathway. 
(A) Localization of NPM1 after IFN-γ treatment. HeLa cells stably expressing 
EGFP-NPM1 were treated without or with IFN-γ (20 ng/ml) for 6 h , followed by 
immunofluorescence analysis with anti-STAT1 (left panels) or anti-IRF1 (right 
panels) antibody. The localization of the proteins was observed by a confocal 
microscope. (B) Expression of JAKs and IFNGRs genes by RT-qPCR. RNA was 
extracted from control or NPM1 knockdown HeLa cells treated without or with 
IFN-γ (20 ng/ml) for 24 h and RT-qPCR was performed using gene-specific 
primers. White bar and black bar indicate the results from control siRNA and 
NPM1 siRNA, respectively. Relative mRNA levels were normalized to GAPDH. 
Three independent experiments were performed and error bars indicate ±SD. 
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Figure 2-2. NPM1 does not affect the early steps of IFN-γ signaling pathway. 
(C) The level of STAT1 Y701 phosphorylation. The cell extracts prepared from 
HeLa cells treated with control or NPM1 siRNA after IFN-γ (20 ng/ml) treatment 
were separated by SDS-PAGE and analyzed by western blotting with anti-STAT1 
phosphorylated at tyrosine 701 (p-STAT1), -STAT1, -NPM1, and -β-actin 
antibodies. Time (min) after IFN-γ treatment was shown at the top of the panel. 
The band intensities of STAT1 and STAT1 (p-Y701) were normalized by that of 
β-actin and relative intensities were graphically shown in right panel. Three 
independent experiments were performed and error bars indicate ±SD. 
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Figure 2-2. NPM1 does not affect the early steps of IFN-γ signaling pathway. 
(D) Localization of STAT1 and IRF1 in NPM1 knockdown cells. HeLa cells were 
treated with control or NPM1 siRNA and stimulated by IFN-γ for the indicated time 
periods. STAT1 or IRF1 was visualized by immunofluorescence staining using 
anti-STAT1 and -IRF1 antibodies, respectively. DNA was stained with TO-PRO-3. 
Localizations were observed by a confocal microscopy.   
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Figure 2-3. NPM1 regulates the IFN-γ induced, but not IFN-β induced 
transcription through direct interaction with STAT1. 
(A and B) Luciferase assays with GAS-Luc and ISRE-Luc reporters. HeLa cells 
treated with control or NPM1 siRNA were transfected with pGAS-TA-Luc (A) or 
pISRE-TA-Luc (B) with pTA-Renilla Luc vectors. Twenty four hours post 
transfection, the cells were stimulated without or with IFN-γ (20 ng/ml) (A) for 24 h 
or IFN-β (1000 IU/ml) (B) for 3 h and subjected to luciferase reporter assay. 
Luciferase activity of each sample was normalized to Renilla luciferase activity to 
calculate relative luciferase activity. Three independent experiments were 
performed and error bars indicate ±SD. The results were statistically analyzed by 
t-test, and ** and * represent P < 0.01 and 0.05, respectively.   
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Figure 2-3. NPM1 regulates the IFN-γ induced, but not IFN-β induced 
transcription through direct interaction with STAT1. 
(C) Immunoprecipitation analysis of STAT1. Cell extracts were prepared from 
HeLa cells treated without or with IFN-γ (20 ng/ml) for 1 h, and the interaction 
between NPM1 and STAT1 was analyzed by immunoprecipitation with control IgG 
or anti-STAT1 antibody. The input (lanes 1 and 2) and immunoprecipitated (lanes 
3–6) proteins were separated by SDS-PAGE and analyzed by western blotting 
with anti-NPM1, -STAT1, and -p-STAT1 antibodies. (D) Purified recombinant 
proteins. Recombinant GST, GST- tagged NPM1 and Flag- tagged STAT1 
proteins were separated by SDS-PAGE and visualized with CBB staining. Lane M 
is a molecular size marker. (E) GST-pull down assay. GST or GST-tagged NPM1 
(lanes 2 and 3, 1 µ g) was mixed and incubated with purified Flag-STAT1. The 
protein bound to GST proteins were examined by western blotting with anti-Flag 
antibody and the GST proteins were visualized by CBB staining. 
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Figure 2-4. NPM1 regulates the transcription of CIITA gene through the IRF1 
binding element. 
(A) Luciferase assay with the CIITA promoter IV. The proximal cis-acting 
elements (CIITA -237, 237 bp upstream and 115 bp downstream of transcription 
start site (+1)) of the CIITA promoter IV was cloned and used for reporter assay. 
5’-deletion mutants, CIITA -154, -82, and -54 were also constructed and 
examined the luciferase activity. HeLa cells treated with control or NPM1 siRNA 
were transfected with pGV-B-CIITA plasmids with pTA-RL vectors. Twenty four 
hours post-transfection, the cells were stimulated without or with IFN-γ (20 ng/ml) 
for 24 h and subjected to luciferase reporter assay. Luciferase activity of each 
sample was normalized by Renilla luciferase activity and the activity of HeLa cells 
treated with control siRNA and without IFN-γ was set as 1.0 and the relative 
reporter activity was calculated. Three independent experiments were performed 
and error bars indicate ±SD. The results were statistically analyzed by t-test, 
and  ** and * represent P < 0.01 and 0.05, respectively. 
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Figure 2-4. NPM1 regulates the transcription of CIITA gene through the IRF1 
binding element. 
(B and C) Luciferase assay with the reporter plasmids containing mutations at 
GAS (B) and IRF1 binding site (C) in the CIITA promoter IV. Experiments and 
data calculation were performed as in (A).   
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Figure 2-5. NPM1 directly interacts with IRF1 through the oligomerization 
domain. 
(A) Immunoprecipitation assay. Cell extracts were prepared from 293T cells 
expressing Flag-tagged IRF1 treated without or with IFN-γ (20 ng/ml) for 6 h, and 
immunoprecipitation was performed with anti-Flag M2 beads. Input (lanes 1 to 4) 
and immunoprecipitated proteins (lanes 5 to 8) were separated by SDS-PAGE 
and subjected to western blotting with anti-Flag and -NPM1 antibodies. (B) 
Diagram of the splicing variants and truncated mutants of NPM1. Black, light gray 
and dark gray boxes indicate oligomerization domain, acidic regions and the 
C-terminal globular domain, respectively. (C and D) GST-pull down assay.  
(Please see next page.) 
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Figure 2-5. NPM1 directly interacts with IRF1 through the oligomerization 
domain. 
(C and D) GST-pull down assay. GST or GST-tagged IRF1 (1 µg/sample) 
immobilized on glutathione sepharose beads were incubated with 
His-tagged NPM1/B23 proteins (1 µg/sample). The beads were extensively 
washed and the bound proteins were separated by SDS-PAGE and visualized by 
CBB staining. The positions of the His-tagged proteins co-precipitated with 
GST-tagged IRF1 are indicated at the left side of each lane.  
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Figure 2-6. A key regulatory role of NPM1 in inflammation and cancer 
development.  
NPM1 is involved in the regulation of the IFN-γ signaling pathway through STAT1 
and IRF1. INF-γ is a well-established proinflammatory cytokine that plays critical 
roles in both the acquired and innate immune systems, host defense, and in tumor 
surveillance. On the other hand, if its activity is excessive, it can enhance the 
inflammatory responses in damaged sites and tumor microenvironments by 
releasing proinflammatory cytokines. NPM1 also regulates the TNFα 
inflammatory response by regulating the NFκB pathway. These results suggest a 
key regulatory role of NPM1 in cancer caused and/or enhanced by inflammation.  
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2-7. Table for primers 
Primers used for RT-PCR 
Primers Sequences 
HLAB-F GCGGCTACTACAACCAGAGC 
HLAB-R GATGTAATCCTTGCCGTCGT 
HLADR-F GAGTTTGATGCTCCAAGCCCTCTCCCA 
HLADR-R CAGAGGCCCCCTGCGTTCTGCTGCATT 
HLADQ-F GGGCTGACTGAAACTATGGC 
HLADQ-R AGGGTGGGAACACAAGGAAG 
STAT1-F CCATCCTTTGGTACAACATGC 
STAT1-R TGCACATGGTGGAGTCAGG 
IRF1-F GAACTCCCTGCCAGATATCGAG 
IRF1-R TGCTCTTAGCATCTCGGCTGGA 
CIITA-F CTGAAGGATGTGGAAGACCTGGGAAAGC 
CIITA-R GTCCCCGATCTTGTTCTCACTC 
NLRC5-F CTGGCCAGTCTCACCGCACAA 
NLRC5-R CCAGGGGACAGCCATCAAAATC 
JAK1-F AAATCGCACCATCACCGTTG 
JAK1-R ATTGTCGTTGGTTCCATGCC 
JAK2-F AGTGGCGGCATGATTTTGTG 
JAK2-R TCTAACACTGCCATCCCAAGAC 
IFNGR1-F TTTCTCCTACCCCTTGTCATGC 
IFNGR1-R TTAGTTGGTGTAGGCACTGAGG 
IFNGR2-F AAGATTCGCCTGTACAACGC 
IFNGR2-R GCCGTGAACCATTTACTGTCG 
GAPDH-F CCACATCGCTCAGACACCAT 
GAPDH-R GCGCCCAATACGACCAAA 
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Chapter 3: Characterization of linker histone H1 variants 
3-1. Introduction 
In eukaryotes, DNA is wrapped around histones consisting of two copies 
each of histones H2A, H2B, H3, and H4, and forms the nucleosome, which is the 
fundamental unit of chromatin. The fifth histone is linker histone H1 that binds to 
linker DNA region [55]. The structure, composed of DNA, core histone octamer 
and linker histone H1, is called a chromatosome [56], which contributes to the 
formation of a higher order chromatin structure. There are eleven H1 variants in 
mammalian cells [57]. Each of the eleven H1 variant genes exists in a single copy 
gene. The H1 variants, H1.1, H1.2, H1.3, H1.4, and H1.5, are synthesized during 
the S phase, whereas H1.0 and H1.X are synthesized independently of S phase. 
These seven H1 variants are expressed in somatic cells. On the other hand, the 
other four H1 variants, H1t, H1T2, HILS1 and H1oo, are expressed in germ cells.  
The linker histone H1 is constructed by three domain structures, which are 
short N-terminal domain, central globular domain, and long C-terminal domain. 
The short N-terminal domain of about 45 amino acids is enriched in basic amino 
acids. The central domain is conserved among H1 variants and has a globular 
conformation. The long C-terminal domain of about 100 amino acids is highly 
enriched in lysine, serine, and proline.  
Several studies suggested the specific functions for H1 variants. For 
example, it was shown that the ability to compact nucleosome was different 
among H1 variants in vitro, and H1 variants have distinct chromatin binding 
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affinities [58-60]. In addition, H1.X was detected in the nucleolus, which is 
different from the patterns of localization of other H1 variants [61]. It was shown 
that H1 variants are differentially expressed and incorporated in chromatin upon 
differentiation of human ES cells or reprograming of adult somatic cells to 
pluripotency [62]. Microarray analysis using human breast cancer cells showed 
that the expression of a different subset of genes was affected in individual H1 
variant knockdown [63]. A specific role for regulating the gene expression 
mediated of particular H1 variant has been reported. Mouse H1b (the homologues 
of human H1.5) and MsX1 bind to a key regulatory element of MyoD, a central 
regulator of skeletal muscle differentiation, and repress the expression of MyoD 
gene, which results in the inhibition of muscle differentiation [64]. Furthermore, 
distribution patterns of linker histones have been reported to be different [65]. For 
example, H1.0 is enriched at 5S rRNA genes and telomeric satellites, whereas 
H1.X is enriched in actively transcribed genes. These studies raised a possibility 
that H1 variants have distinct functions. However, the detailed functional 
differences among H1 variants and their action mechanism remain unknown.   
In this study, to understand the distinct function of seven somatic H1 variants, 
I examined their cellular behaviors by FRAP assay. Interestingly, I found that their 
cellular mobility is different and classified into three groups, those with fast (H1.X), 
intermediate (H1.1 and H1.2), and slow group (H1.3, H1.4, H1.5, and H1.0). To 
reveal the mechanism by which H1 variants show different cellular behaviors, I 
biochemically examined their intrinsic DNA, nucleosome, and histone chaperone 
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binding activity of H1 variants in vitro. I demonstrated that the DNA, nucleosome, 
and histone chaperone binding activity of H1.X are lower than those of H1.1 and 
H1.0 in vitro. It is suggested that those distinct binding activity of H1 variants 
generate the differential patterns of chromatin structure and gene expression.   
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3-2. Materials and Methods 
3-2-1. Plasmid construction 
To construct pGEX6P-1-H1.0, pEGEX6P-1-H1.1, pEGEX6P -H1.X, pEGEX6P 
-H1.2, pEGEX6P -H1.3, pEGEX6P -H1.4, and pEGEX6P -H1.5, cDNAs were 
amplified from the genomic DNA extracted from HeLa cells by PCR with primer 
sets, H1.0-F and H1.0-R, H1.1-F and H1.1-R, and H1.X-F and H1.X-R, H1.2-F 
and H1.2-R, H1.3-F and H1.3-R, H1.4-F and H1.4-R, H1.5-F and H1.5-R, 
respectively. Amplified DNAs were digested with BamH1 and ligated into a BamH 
I-digested pEGFPC1 vector (Clontech). Primer sets for cloning of linker histones 
are listed in table, 3-6. The plasmids, pGEX6P-1-H1.0, pEGEX6P-1-H1.1, 
pEGEX6P -H1.X, pEGEX6P -H1.2, pEGEX6P -H1.3, pEGEX6P -H1.4, and 
pEGEX6P -H1.5 are digested by Bam HI and ligated into Bam HI digested 
pGEX6P, respectively. Plasmids pET-14b-NPM1, pET14b-TAF-Iβ, 
pET14b-sNASP, pET14b-NAP1L1, pET14b-NAP1L4, pcDNA3.1-sNASP, 
pcDNA3-H1.X-Flag, pET14b-H1.0, pET14b-H1.1, and pET14b-H1.X were 
described previously [14,66,67]. 
Four human core histone cDNAs cloned in pET22b vector were transferred to 
pET14b vector (Novagen) with appropriate restriction enzymes and generated 
pET14b-H2A, pET14b-H2B, pET14b-H3, and pET14b-H4.  
3-2-2. Cell culture, transfection and reagents 
HeLa and HEK293T were maintained in Dulbecco’s modified Eagle’s medium 
(Nacalai Tesque) supplemented with 10% fetal bovine serum and 
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penicillin-streptomycin solution (Nacalai Tesque). Cell lines, HeLa H1.0-Flag, 
HeLa H1.1-Flag, and HeLa H1.X-Flag were established as described previously 
[66]. Transient transfection of plasmid DNA was performed using Gene Juice 
(Novagen) according to the manufacturer’s instruction. To establish stable cell 
lines, HeLa cells were transfected with pGEX6P-1-H1.0, pEGEX6P-1-H1.1, 
pEGEX6P -H1.X, pEGEX6P -H1.2, pEGEX6P -H1.3, pEGEX6P -H1.4, and 
pEGEX6P -H1.5. Neomycin-resistant cells were selected by G418. 
3-2-3. Purification of recombinant proteins 
To express and purify the recombinant proteins, BL21 (DE3)-RP (Novagen) was 
transformed with pGEX6P-1-H1.0, pEGEX6P-1-H1.1, pEGEX6P -H1.X, 
pEGEX6P -H1.2, pEGEX6P -H1.3, pEGEX6P -H1.4, pEGEX6P -H1.5, pET, 
pET-14b-NPM1, pET14b-TAF-Iβ, pET14b-sNASP, pET14b-NAP1L1, 
pET14b-NAP1L4, pET14b-H1.0, pET14b-H1.1, and pET14b-H1.X. The 
transformed E.coli were grown at 37oC until OD600 reached 0.4. Expression of the 
recombinant proteins was incuduced by addition of 0.1 mM isopropyl 
β-D-thiogalactopyranoside at 30oC for 3 hours. Bacterial cell lysates were 
sonicated in buffer A (50 mM Tris-HCl (pH 7.9), 0.1% Triton X-100, and 1 mM 
phenylmethylsulfonyl fluoride (PMSF)) containing 100 mM NaCl for GST-tagged 
proteins or in His-binding buffer (50 mM Na2HPO4, 50 mM NaH2PO4, 10 mM 
Imidazole) containing 300 mM NaCl for His-tagged proteins. His-tagged proteins 
were purified with HIS-Select Nickel affinity gel according to the manufacturer’s 
instruction (Sigma-Aldrich). Purified proteins were dialyzed against buffer H (20 
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mM HePes-NaOH (pH8.0), 50 mM NaCl, 0.1 mM EDTA, 10% (v/v) glycerol, 1 mM 
DTT, 0.5 mM PMSF) or H1 buffer for H1 proteins (20 mM, Tris-HCl (pH7.9), 200 
mM NaCl, 0.1 mM PMSF) for 6 hours at 4oC. Dialyzed H1 proteins were 
fractionated by a Mono S column (GE Healthcare) and purified with salt gradient 
from 0.2 M to 1 M NaCl. GST-tagged proteins were purified with Glutathione 
sepharose (GE Healthcare). Flag-NCL was expressed in 293T cells using 
pcDNA3.1-NCL. The Flag-NCL was immunoprecipitated using anti-Flag M2 
beads (Sigma-Aldrich), treated with micrococcal nuclease to remove RNAs, and 
eluted with Flag peptide (Sigma-Aldrich). The expression and purification of 
recombinant core histones are described previously [68]. 
3-2-4. Reconstitution and purification of nucleosome core particles 
NCPs were assembled with the 196 bp 5S rRNA gene fragment and core histones 
by salt dilution method [67]. Reconstituted NCPs (200 µL) incubated at 42°C for 1 
h were loaded on 15%–35% glycerol gradient in 10 mM Tris-HCl (pH7.9), 1 mM 
DTT (2.2 mL). The samples were centrifuged at 54,000 rpm for 8 h at 4°C in S55S 
rotor (Hitachi Koki, 202 SC100GXII), and fractions (100 µl) were collected from 
the top. 
3-2-5. DNA/NCP and histone chaperone binding assays 
DNA or purified NCP (10 nM DNA) was mixed and incubated with increasing 
amounts of His-tagged H1 proteins in a buffer containing (15 mM Tris-HCl pH7.9, 
150 mM NaCl, 12% glycerol, and 200 µg/ml BSA) at 30°C for 30 min. Samples 
were separated on 6% native-PAGE in 0.5×TBE at 100 V for 80 min. DNA was 
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visualized by GelRed (Biotium) staining. For histone chaperone activity assay on 
DNA, His-tagged sNASP, NAP1L1, NAP1L4, TAF-Iβ, NPM1 or Flag-tagged NCL 
was incubated with His-tagged H1, and further incubated with the 196 bp 5S 
rDNA gene fragments for 30 min at 30oC. For histone chaperone activity assay on 
NCP, His-tagged TAF-Iβ or NPM1 was incubated with His-tagged H1, and further 
incubated with NCPs for 30 min at 30oC. Samples were separated on 6% 
native-PAGE in 0.5×TBE at 100 V for 80 min. DNA was visualized by GelRed 
(Biotium) staining. For histone chaperone binding assays, His-tagged histone 
chaperone proteins were mixed with increasing amount of His-tagged H1 and 
incubated for 30 min at room temperature in a buffer containing (15 mM 225 
Tris-HCl pH7.9, 150 mM NaCl, and 12% glycerol). Samples were separated on 
native-PAGE in 0.5×TBE at 100V for 90 min. Proteins were visualized by CBB 
staining. 
3-2-6. Immunoprecipitation and GST-pull down 
Nuclear protein-rich extracts from HeLa cell lines expressing Flag-tagged H1.X 
were prepared with the standard method [69]. Briefly, cells were suspended in 5 
packed cell volume of buffer A (10 mM Hepes (pH 7.9), 1.5 mM MgCl2, 10 mM 
KCl, 0.5 mM DTT, 0.5 mM PMSF) and incubated on ice for 10 min. Cells were 
centrifuged and the buffer was removed. Cells were suspended in 1 mL of buffer 
A, homogenized in Dounce homogenizer and the intact cells were separated from 
the cytoplasmic protein-rich fraction by centrifuge. The isolated nuclei were 
re-suspended in buffer C (20 mM Hepes (pH 7.9), 25% (v/v) glycerol, 0.42 M NaCl, 
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1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM PMSF and 0.5 mM DTT), homogenized 10 
strokes and incubated on ice for 30 min. The soluble nuclear protein-rich extracts 
were recovered by centrifuge. The extracts were dialyzed in dialysis buffer (50 
mM Tris (pH 7.9), 100 mM NaCl, 1 mM DTT, 0.5 mM PMSF, and 10% (v/v) 
glycerol). The dialyzed extracts were supplemented with 0.1% Triton X-100 and 
mixed with Flag M2 beads (Sigma-Aldrich). Precipitated proteins were eluted with 
the same buffer containing 0.1 mg/mL of Flag peptide (Sigma-Aldrich). Eluted 
proteins were analyzed by SDS-PAGE followed by Western blotting. 
For GST-pull down assays, glutathione sepharose beads immobilized 
GST-tagged H1 were mixed with His-tagged sNASP, NAP1L1, NAP1L4, TAF-Iβ, 
NPM1(B23.1) or Flag-tagged NCL and incubated at 4oC for 1 h followed by 
extensive washing with buffer A containing 300 mM NaCl or 200 mM NaCl. 
Proteins were eluted from the beads by an SDS sample buffer, separated by 
SDS-PAGE, and visualized by CBB staining or western blotting. 
3-2-7. FRAP assay 
HeLa cells stably expressing EGFP-tagged linker histone H1 proteins grown on 
35-mm glass-base dishes (AGC Techno Glass) were used for FRAP analysis. 
The dish was set on inverted microscope (LSM EXCITER; Carl Zeiss 
Microimaging) in an air chamber containing 5% CO2 at 37oC and analyzed as 
previously described [70]. The data were represented as mean values ± SD from 
at least 10 experiments.  
3-2-8. Antibodies 
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Following antibodies were used in this study: Anti-TAF-I (KM1725, 1:100) [71], 
anti-NPM1/B23 (Thermo Fisher Scientific (32-5200) 1:1000), anti-nucleolin (D6, 
Santacruz Biotechnology (SC-17826), 1:1000), anti-NASP (Proteintech 
(11323-1-AP), 1:1000), anti-Flag M2 (Sigma-Aldrich (F1804), 1:1000). 
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3-3. Results 
3-3-1. Cellular behaviors of individual H1 variants 
To examine the cellular behaviors of H1 variants, FRAP assays were carried 
out using HeLa cell lines stably expressing N-terminally GFP-tagged H1.0, H1.1, 
H1X, H1.2, H1.3, H1.4, or H1.5. GFP-tagged H1 variants were detected in 
nucleus, whereas H1.X was also detected in the nucleolus. I observed that H1 
variants show the distinct cellular behavior (Figure 3-1A). Cellular mobility was 
classified into three groups, those with fast (H1.X), intermediate (H1.1 and H1.2), 
and slow group (H1.3, H1.4, H1.5, and H1.0) (Figure 3-1B). The recovery rate of 
H1.X was highest among H1 variants (Figure 3-1B).  
3-3-2. DNA and nucleosome binding activity of H1 variants in vitro 
Next, I questioned how the distinct cellular mobility of H1 variants is 
determined. It has been reported that the cellular mobility of H1 directly reflects 
the binding strength of H1 to chromatin [72]. Therefore, I examined the DNA and 
nucleosome binding activities of H1 variants in vitro. To this end, nucleosome core 
particle (NCP) is reconstituted with four recombinant core histones (Figure 3-2A) 
and the 196 bp long DNA fragment by salt dilution method. Reconstituted NCPs 
were purified using a glycerol gradient (Figure 3-2B). The peak NCP fractions 
were used for binding assays (Figure 3-2B, lane 12 to lane 14). The reconstituted 
NCP was detected as two bands on native PAGE due to the different positioning 
of NCP along the 196 bp DNA fragments. The H1 variants used for this assay 
were H1.X, H1.0 and H1.1, which were representative of each group of cellular 
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mobility. His-tagged H1.X, H1.0 and H1.1 were purified by ion exchange column 
(Figure 3-2C). DNA and NCP (Figure 3-2D top and bottom, respectively) were 
mixed with increasing amounts of H1.0, H1.1, and H1.X, and the complexes were 
separated using native PAGE. All H1 variants, H1.0, H1.1, and H1.X, bound to 
both naked DNA and NCP in a dose-dependent manner, and their affinities 
toward NCP were higher than those toward naked DNA, suggesting that linker 
histones preferred to bind the structured region (Figure 3-2D). In addition, DNA 
and NCP binding activities of H1.X were lower than those of H1.1 and H1.0. This 
result indicates that the highest cellular mobility of H1.X could be explained by its 
lower DNA and NCP binding activities.  
3-3-3. Interaction between H1 and histone chaperones 
Histone chaperones help to assemble H1 onto nucleosome and 
disassemble H1 from nucleosome. Therefore, histone chaperones are also 
involved in the regulation of cellular mobility of H1. To examine whether seven H1 
variants associate with previously known linker histone chaperones in vitro, GST- 
pull down assays were performed (Figure 3-3A). Although a lot of bands were 
observed in GST-tagged H1 variants (Figure 3-3A, lane 3 to 9), the top band 
indicated the full-length product. All histone chaperones except for sNASP were 
pulled-down with GST-tagged H1 variants in a buffer containing 300 mM NaCl, 
but not with GST alone, indicating that these histone chaperones directly 
associate with individual H1 variants. By reducing the salt in a buffer, sNASP was 
also pulled-down (Figure 3-3A, bottom). It suggests that binding of H1 to sNASP 
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was lower than those to other histone chaperones. Furthermore, to examine the 
interaction between histone chaperones and H1.X in vivo, immunoprecipitation 
assay was performed using the nuclear extracts prepared from HeLa cells stably 
expressing Flag-tagged H1.X. Flag-tagged H1.X was successfully purified from 
the extracts (Figure 3B, lane 7 and 8). The histone chaperones 
nucleophosmin/B23, Nucleolin (NCL), and TAF-I, but not sNASP were co-purified 
with Flag-tagged H1.X, suggesting that these histone chaperones have a potential 
ability to regulate the dynamic behavior of H1 variants in the nucleus.  
3-3-4. Histone chaperone activity for H1 variants 
Next, I quantitatively analyzed the histone chaperone binding activity of H1 
variants in vitro (Figure 3-4A to C). Because both NPM1 and TAF-I are highly 
acidic proteins, they move to the cathode on native PAGE. Free NPM1 and TAF-I 
(indicated by arrow head) were reduced by increasing amounts of H1 variants 
(Figure 3-4B). TAF-I was detected with a single band by native PAGE, and the 
amount of free TAF-I was quantitatively analyzed (Figure 3-4C). The result 
demonstrated that the affinity of TAF-I to H1.X was clearly lower than that to H1.0 
and H1.1. Because NPM1 alone was not accumulated into a single band on 
native PAGE, I failed to quantitatively estimate the amount of free NPM1 after the 
addition of H1. However, free NPM1 bands were still detected after addition of 16 
pmole of H1.X, whereas it was not detected after the addition of 16 pmole of H1.1 
or H1.0 (Figure 3-4B, compare lanes 4, 10, and 16), indicating that the affinity of 
NPM1 to H1.X was also lower than that to H1.0 and H1.1.  
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The functions of histone chaperone are to inhibit random DNA binding of 
histones and mediate proper histone-DNA formation. I next examined whether 
NCL, sNASP, NAP1L1, NAP1L4, TAF-I, and NPM1 function as chaperones for H1 
(Figure 3-4D to F). Consistent with the data shown in Figure 3-2D, H1 randomly 
bound to DNA (Figure 3-4D to F, lane2 to 5) and DNA binding activity of H1.X was 
lower than those of H1.0 and H1.1 (Figure 3-4F, lane2 to 5). However, the DNA 
binding of H1 was inhibited by the addition of chaperones except for NCL. 
Although I showed that NCL interacted with H1 (Figure 3-3A), I could not evaluate 
the histone chaperone function of NCL in this assay system. Next, I examined the 
effect of NPM1 and TAF-I on the H1-NCP formation. When NCP was mixed with 
high concentrations of H1, large aggregates were observed and could not enter 
native PAGE (Figure 3-4G to I, lane 2). However, the H1–NCP formation was 
appeared by adding the increasing amounts of TAF-I and NPM1 (Figure 3-4G to I, 
lanes 5–9 and 10–14, respectively). The excess amount of TAF-I disrupted the 
deposition of all linker histones on NCPs and free NCPs were clearly detected. 
From these results, it was demonstrated that NPM1 and TAF-I inhibit the random 
DNA binding of H1, and contributes to the proper H1-NCP formation. Furthermore, 
the chaperone activity of NPM1 and TAF-I were different from each other. 
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3-4. Discussion 
In this study, I examined the cellular behavior of H1 variants by FRAP assay. 
The cellular mobility of H1 variants was different and classified into three groups, 
those with fast (H1.X), intermediate (H1.1 and H1.2), and slow group (H1.3, H1.4, 
H1.5, and H1.0). In addition, I analyzed the mechanism by which H1 variants 
show different cellular behavior. Biochemical analyses demonstrated that DNA 
and NCP binding activities of H1.X were lower than those of H1.1 and H1.0.  
Since histone chaperone is also involved in the cellular behavior of H1, I 
examined the histone chaperone binding activity of H1 variants. Previously known 
histone chaperones, NCL, sNASP, NAP1L1, NAP1L4, TAF-I, and NPM1 directly 
interacted with seven somatic H1 variants. The quantitative biochemical analyses 
demonstrated that H1.X shows the lower binding ability with histone chaperones, 
NPM1 and TAF-I compared with H1.0 and H1.1. These results suggest that lower 
DNA, nucleosome and chaperone binding activities of H1.X contribute to the 
highest cellular behavior of H1.X.  
The chaperone activity of TAF-I and NPM1 toward H1 was different. I 
showed that TAF-I and NPM1 deposited the H1 onto nucleosome, whereas TAF-I, 
but not NPM1, removed the H1 from nucleosome. This can be explained by 
binding preference of H1 toward chaperones and nucleosome. It is likely that H1 
preferentially bind to the DNA compared with NPM1, thereby H1 cannot be 
removed from nucleosome by NPM1. So far, it has not been reported that there is 
a specific chaperone for H1 variant, however it is possible that unknown 
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chaperone exists and involved in the distinct cellular behavior. 
Although my study did not reveal which domain structures of H1 contribute 
to the dynamic behavior in the cells, previous studies have reported that the 
dynamics of H1 are regulated by both central globular domain (GD) and 
C-terminal domain (CTD) [73], and the deletion of the N-terminal domain (NTD) 
also decreased the stable chromatin binding of linker histones [74]. Later, my 
laboratory member performed the domain swapping analysis. He constructed 
chimeric H1 proteins that comprised H1.0 containing NTD, GD, and CTD of H1.X 
and H1.X containing NTD, GD, and CTD of H1.0. It was demonstrated that the 
mobility of H1.0 significantly increased by the substitution of either its GD or CTD 
with that of H1.X. This result suggests that both GD and CTD of H1.X contribute to 
the cellular behavior of H1.X in the nucleus. Further biochemical analyses 
indicated that the CTD of H1.X has a weak DNA and nucleosome binding of H1.X 
among H1 variants. It is known that CTD of linker histones is enriched in basic 
amino acids, which are required for the interaction with DNA or chaperones. The 
basic amino acid content of H1.X (34%) is lower than that of H1.0 CTD (49%). It 
suggests that this difference may generate the distinct DNA, nucleosome and 
histone chaperone binding activities.  
The DNA binding activity of H1 is also affected by DNA methylation and their 
post-translational modification [75-77]. Therefore, it is interesting to examine the 
effect of DNA methylation and post-transcriptional modification of H1 on the DNA 
binding activity of H1 in future. These analyses will be helpful to more closely 
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understand the cellular behavior of H1.  
Previous study reported that individual H1 variant knockdown affected a 
different subset of genes [63]. It is suggested that distinct characteristics of H1 
generate the differential patterns of chromatin structure and affect the gene 
expression.  
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3-5. Figures and legends 
 
Figure 3-1. Cellular behaviors of individual H1 variants. 
(A) FRAP assay. Stable HeLa cell lines expressing EGFP-H1 variants were 
examined for fluorescence recovery after photobleaching assays (FRAP). 
Regions marked by red were bleached with 488 nm-laser line and the EGFP 
signal was measured every 1 sec. EGFP, EGFP-H1.1, -H1.2, -H1.3, -H1.4, -H1.5, 
-H1.1, and -H1.X expressing cells were examined and results for EGFP-H1.0, 
EGFP-H1.1, and EGFP-H1.X are shown. Ten cells were examined for FRAP 
assays for each H1 variants and the intensity of bleached area was normalized 
with that of non-bleached area. (B) Recovery rate. The averaged relative intensity 
was plotted as a function of time (sec) after photobleaching.  
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Figure 3-2. DNA and nucleosome binding activity of H1 variants in vitro. 
(A) Purified recombinant histone octamers. Recombinant proteins were separated 
by 12.5% SDS-PAGE, and visualized with Coomassie Briliant Blue (CBB) staining. 
Lane M indicates molecular size markers. (B) NCP purification by 15-35% 
Glycerol gradient. Reconstituted NCP sample was put on 15-35% glycerol 
gradient and centrifuged at 54,000 rpm for 8 hours at 4oC. Fractions (100 µl) were 
recovered from the top of the tube. The purification of nucleosome was confirmed 
by 6% non-denaturing PAGE. DNA was visualized by GelRed staining. Fractions 
12-14 were used for the DNA/NCP binding assays.  
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Figure 3-2. DNA and nucleosome binding activity of H1 variants in vitro. 
(C) Purified recombinant H1 proteins. Recombinant His-H1.X, His-H1.1, His-H1.0 
(lanes 1–3) were separated by 12.5% SDS-PAGE, and visualized with Coomassie 
Brilliant Blue (CBB) staining. Lane M indicates molecular size markers. (D) DNA 
and NCP binding activity of H1 variants. Naked DNA (196 bp-5S rRNA gene 
fragment, upper panel) or NCP assembled on the same DNA fragment (bottom 
panel) (0.01 µM each) were mixed without or with 0.02, 0.04, 0.06, 0.08, and 0.1 
µM of H1.0 (lanes 2–6), H1.1 (lanes 7–11), and H1.X (lanes 12–16), and 
incubated at 30°C for 30 min, followed by native PAGE analysis. The positions of 
free DNA and NCP are indicated by arrowheads. The intensities of free DNA 
(upper panel) and NCP (blank arrowheads in the bottom panel) were measured 
and the amounts of free DNA/NCP were graphically shown at the right. Two 
independent experiments were performed and error bars indicate ± SD.    
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Figure 3-3. Interaction between H1 and histone chaperones. 
(A) GST-pull down assay.  GST, GST-H1.1, GST-H1.2, GST-H1.3, GST-H1.4, 
GST-H1.5, GST-H1.0, or GST-H1.X (1 µg each) were expressed and immobilized 
on glutathione sepharose beads (Top panel), and mixed with 1 µg of Flag-NCL, 
sNASP, NAP1L1, NAP1L4, His-TAF-I, or His-NPM1. After extensive washing in a 
buffer containing 300 mM or 200 mM NaCl only for sNASP (Bottom panel), 
proteins on the beads were analyzed by SDS-PAGE and western blotting with 
anti-NCL, -sNASP, -NAP1L1, -NAP1L4, -TAF-I, and –NPM1 antibodies.  The 
membrane was stained with CBB (Top panel).   
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Figure 3-3. Interaction between H1 and histone chaperones. 
(B) Interaction of H1.X with linker histone chaperones in the extracts. Histone 
chaperones co-immunoprecipitated with FLAG-tagged histones from HeLa cell 
extracts were detected by western blotting analyses. Cytoplasmic extracts (CE) 
and nuclear extracts (NE) prepared from HeLa cell lines expressing FLAG-tagged 
histones were used. Con (Control) indicates HeLa cells without expression of 
tagged protein. Input is 0.5% of total extract volume and Immunoprecipitated 
proteins (IP) is 20% of total elution volume These were separated by 13% 
SDS-PAGE followed by western blotting with anti-FLAG tag, -sNASP, -TAF-I, 
-Nucleolin, -NAP-1, -NPM1. Positions of proteins are indicated by arrowhead.  
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Figure 3-4. Histone chaperone activity for H1 variants. 
(A) Purified proteins. His-tagged TAF-I and NPM1 (200 ng each) were separated 
by 10% SDS-PAGE and visualized by CBB staining. Lane M indicates molecular 
size markers. (B) Native PAGE analyses of linker histone–histone chaperone 
complex formation. NPM1 (top panels) and TAF-I (bottom panels) (1.6 µM each) 
were incubated with increasing amounts (0, 0.8, 1.2, 1.6, 2.0, and 2.4 µM) of 
His-H1.0, His-H1.1, and His-H1.X at room temperature for 30 min. The mixture 
was separated by 6% native PAGE, and visualized by CBB staining. Positions of 
free chaperones were shown by arrowheads. The amounts of free TAF-I after the 
addition of linker histones were quantitatively analyzed by Image J, and the 
relative intensity was plotted as shown in (C). 
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Figure 3-4. Histone chaperone activity for H1 variants. 
(D) DNA binding activity. Recombinant His-H1.0 (0, 10, 20, 50, 100 ng) and 
indicated chaperones (100 ng) were pre-incubated. After pre-incubation, the 196 
bp 5S rRNA gene fragments (10 ng) were added and incubated. The complexes 
were separated by 6% non-denaturing PAGE, and DNA was visualized by Gel 
Red staining. Same experiments were performed using H1.1 (E) and H1.X (F). 
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Figure 3-4. Histone chaperone activity for H1 variants. 
(G) Nucleosome binding activity. NCPs (0.23 pmols) were mixed without (lane 1) 
or with His-tagged H1, GST-NPM1, or GST-TAF-I. His-tagged H1 variants were 
pre-incubated with GST-TAF-I (lanes 5–9) or GST-NPM1 (lanes 10–14) in the 
following ratio (H1: chaperone, 1:1,1:5,1:10,1:20,1:30) and then NCP (0.23 
pmols) was added and further incubated. The results of histone chaperone activity 
with His-H1.1, His-H1.0, and His-H1.X were shown in left (G), right upper panels 
(H), and bottom panel (I), respectively. The mixtures were loaded on 6% native 
PAGE and DNA was visualized by Gel Red staining. Positions of free DNA, NCP, 
and H1-bound NCP are indicated at the right side of the gels.  
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3-6. Table for primers 
Primer sequences for cloning of linker histones 
Primers Sequences 
H1.0-F AGCTGGATCCGCCGCCACCATGACCGAGAATTCCACGTC 
H1.0-R AGCGGATCCTCACTTCTTCTTGCCGGCCC 
H1.1-F AGCTGGATCCGCCGCCACCATGTCTGAAACAGTGCCTCC 
H1.1-R AGCGGATCCTTACTTTTTCTTGGGTGCCG 
H1.X-F AGCTGGATCCGCCGCCACCCATATGTCCGTGGAGCTCGAGGA 
H1.X-R AGCGGATCCTCACTTGCGGCCCTTGGGCA 
H1.2-F AAAGGATCCATGTCCGAGACTGCTCCTGC 
H1.2-R AAAGGATCCCTATTTCTTCTTGGGCGCCG 
H1.3-F AAAGGATCCATGTCGGAGACTGCTCCACT 
H1.3-R AAAGGATCCTCACTTTTTCTTCGGAGCTG 
H1.4-F AAAGGATCCATGTCCGAGACTGCGCCTGC 
H1.4-R AAAGGATCCCTACTTTTTCTTGGCTGCCG 
H1.5-F AAAGGATCCATGTCGGAAACCGCTCCTGC 
H1.5-R AAAGGATCCCTACTTCTTTTTGGCAGCCG 
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Chapter 4: A mechanism maintaining the amount of H1  
4-1. Introduction 
Previous studies reported the gene disruption of H1 variants in mice. [78,79]. 
It was shown that single-knockout of H1 variant genes: H10, H1c, H1d, or H1e 
(murine homologues of human H1.0, H1.2, H1.3, and H1.4), and 
double-knockouts of H1 variant genes: H1c/ H10, H1d/ H10, or H1e/ H10 in mice 
did not affect mice development. Interestingly, total amount of H1 was not 
changed by either single or double knockout of H1 variants, because the other H1 
variants compensated the lost amount of H1. Importantly, these results suggest 
that the functions of H1 variants are redundant among H1 variants. Furthermore, 
these results prompted me to hypothesize that there should be a mechanism 
maintaining the amount of H1. However, this mechanism cannot function anymore 
when three H1 variant genes were knocked out at the same time [80]. Mice 
lacking three H1 variant genes, H1c, H1d, and H1e, dies by E11.5 with a broad 
range of defects. The H1 to core histone stoichiometry in triple-H1-null embryos 
was found to be 50% of that in wild-type embryos. This H1 depletion caused the 
core histone modifications and chromatin structure changes, including decreased 
nucleosome repeat length and decreased local chromatin compaction [81]. 
However, microarray analysis of H1 triple-knockout mice revealed that expression 
of only a small number of genes is affected [81]. Many of the affected genes are 
imprinted genes or are genes on the X chromosome, which are normally 
regulated by DNA methylation. The reduced level of H1 decreased the DNA 
 69 
methylation of CpGs within the regulatory regions of their genes, suggesting that 
H1 participates in regulation of DNA methylation. These results suggest that the 
amount of H1 is essential for mouse development and involved in the regulation of 
chromatin structure and gene expression through epigenetic modification.  
My research aim is to reveal the molecular mechanism maintaining the 
amount of H1. To examine whether H1 depletion increases the expression of the 
other H1 variant genes, I established the HCT116 cell lines stably expressing 
H1.4 shRNA or H1.0 shRNA. In addition, to examine the protein expression of 
individual H1 variants in H1.4 knockdown cells, I learned the method of Triton 
Acid Urea (TAU) gel and Reverse Phase-high Performance Liquid 
Chromatography (RP-HPLC).   
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4-2. Materials and methods 
4-2-1. Cell culture, transfection and reagents 
HeLa cells, HEK293T cells and HCT116 cells were maintained in Dulbecco’s 
modified Eagle’s medium (Nacalai Tesque) supplemented with 10% fetal bovine 
serum and penicillin-streptomycin solution (Nacalai Tesque). HEK293T cells were 
transfected with three lentivirus-packaging plasmids (pMDLg/pRRE, pMD2-G2, 
pRSV-Rev), Luciferase shRNA (Sigma-Aldrich, pLKO.1-puro Luciferase shRNA 
Control plasmid DNA) and either H1.4 shRNA (Sigma-Aldrich, HIST1H1E 
MISSION shRNA Lentiviral Transduction Particles) or H1.0 shRNA 
(Sigma-Aldrich, H1F0 MISSION shRNA Lentiviral Transduction Particles) by 
JetPRIME (Polyplus-transfection) reagent according to the manufacturer’s 
instructions. After 72 hours post transfection, supernatants containing lentivirus 
particles were filtrated by 0.45 µm PVDF and collected by centrifuge with 6 µg/ml 
polybrene. Lentivirus particles were added to HCT116 cells and incubated for 48 
hours. Cells were selected by puromycin.  
4-2-2. Isolation of histone proteins 
HCT116 cells or HeLa cells were homogenized with homogenization buffer (0.32 
M sucrose, 0.1% Triton X-100, 5 mM MgCl2, 10 mM Tris pH7.2, 1% thiodiglycerol, 
0.5 mM phenylmethylsulfonyl fluoride). Crude nulei were collected by 
centrifugation. The pellet was re-suspended in high salt buffer (0.25 M KCl, 10 
mM Tris pH 7.2, 5 mM MgCl2, 0.5 mM PMSF) and incubated on ice for 20 min. 
Crude chromatin was pelleted by centrifugation. The crude chromatin pellet was 
 71 
resuspended in cold 0.2 M H2SO4 and incubated on ice for 20 min. Insoluble 
material was pelleted by centrifugation. Supernatant was precipitated with 35% 
trichloroacetic acid (TCA) and kept on ice for 1 hour. After centrifugation, histone 
pellet was washed by acetone three times. To isolate linker histone H1 proteins, 
crude chromatin was resuspended in 5% HClO4 and incubated 20 min. Insoluble 
material was pelleted by centrifugation. Supernatant was precipitated 6 volume of 
acetone containing 10 mM HCl and kept on ice for 1 hour. After centrifugation, H1 
pellet was washed by cold acetone containing 10 mM HCl and washed twice by 
acetone.  
4-2-3. Triton acid urea gel 
The separating gel consisted of 40%:0.08% acrylamide:biascrylamide, 8M Urea 
and 5% acetic acid. The samples were prepared and dissolved in TAU sample 
buffer (8M Urea, 5% acetic acid, 0.1M DTT, 0.05% Methyl green, 5% 
Thiodiglycerol, and 5% glycerol). Electrophoresis was performed at 200 V for 2 
hours in running buffer containing 5% acetic acid. 
4-2-4. Reversed-phase HPLC separation of histones 
Standard C-18 column (Phenomenex) was used. The histone sample from HeLa 
cells was run by acetonitrile gradient. The gradient used on an Waters Alliance 
2695 Separations Module consisted of 0–25% B in 10 min, 25–55% B in 55 min, 
55-90% B in 5 min (A, 0.1% acetic acid; B, 95% acetonitrile in 0.1% acetic acid). 
To identify the H1 variant, fractionated samples were collected and lyophilized in a 
SpeedVac for 4 hours. Lyophilized fractions were re-dissolved in ddH2O and 
 72 
analyzed by multidimensional liquid chromatography (LTQ Orbitrap Velos) mass 
spectrometry. 
4-2-5. RT-qPCR 
Total RNA was extracted using RNeasy Kit (Qiagen) according to the 
manufacturer’s instructions. cDNA was prepared from purified RNA (1 µg) by 
using ReverTraAce (Toyobo) with oligo dT primer. Real-time PCR was carried out 
with SYBR Green Real time PCR Master Mix-Plus (Toyobo) in the Thermal Cycler 
Dice Real-Time PCR system (TaKaRa). Primer sets for RT-PCR are listed in table, 
4-6.  
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4-3. Results 
4-3-1. The effect of H1.4 or H1.0 depletion on the expression of the other H1 
variant genes. 
Firstly, I tested whether decreased amount of one H1 variant gene results in 
the mRNA up-regulation of the other H1 variant genes by RT-qPCR even in 
cultured cancer cells (Figure 4-1). I established HCT116 cell lines stably 
expressing either H1.4 shRNA or H1.0 shRNA and used them for this assay. The 
expression of H1.4 mRNA was reduced about 70% by H1.4 shRNA. The depletion 
of H1.4 resulted in 3 fold and 1.5 fold increase of H1.0 and H1.2 mRNA, 
respectively (Figure 4-1A), whereas the expression of H1.X mRNA was not 
affected by H1.4 depletion. The expression of H1.1, H1.3 and H1.5 mRNA was 
not detected in HCT116 cells. On the other hand, the expression of H1.0 mRNA 
was reduced about 60% by H1.0 shRNA, while the expression of H1.2 and H1.4 
mRNA was also reduced by H1.0 shRNA (Figure 4-1B). The result showed that 
the depletion of H1.0 increased the expression of H1.X mRNA about 2 fold. These 
results suggest that a mechanism maintaining the amount of H1 is regulated 
before translation. Furthermore, I found some trends for their regulation. For 
example, when H1.4 is depleted, the expression of H1.0 and H1.2 are increased, 
and when H1.0 is depleted, the expression of H1.X is increased.  
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4-3-2. Separation of H1 variant proteins 
Next, to examine whether the depletion of H1 increases the protein 
expression of other H1 variants, I analyzed the histone proteins isolated by acid 
extraction from HeLa cells. The procedure of histone extraction was described in 
Figure 4-2A. Briefly, cells were lysed using hypotonic buffer and intact nuclei were 
collected. The nuclei were extracted in acidic conditions to selectively isolate 
histones. In addition, linker histones were extracted using HClO4. Because there 
were not specific antibodies for linker histone variants, I first tried to separate the 
H1 variant proteins by TAU gel (Figure 4-2B). TAU gel is known to be able to 
separate certain histone variants, such as H3 variants H3.1, H3.2, H3.3 by binding 
of the triton X-100 to hydrophobic regions of the proteins. Linker histones were 
isolated by HClO4, however, these histones were not individually separated by 
TAU gel (Figure 4-2B, lane1). Next, I tested whether H1 variant proteins are 
separated by RP-HPLC. Isolated histones were separated by C18 column in an 
acetonitrile gradient (Figure 4-2C). The samples indicated by arrows (Figure 4-2C, 
bottom panel) were separated by SDS-PAGE (Figure 4-2D) and analyzed by 
mass-spectrometry. The results showed that H1.0 was identified in the peak (34 
to 35 min), and H1.2, H1.3, and H1.5 were identified in the peak (52 to 53 min). 
Although I could separate histone H1.0 by RP-HPLC, the other H1 variant 
proteins could not be separated by this method. In future, I will increase the 
retention time and collect samples in short time period.  
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4-3-3. The effect of H1.4 depletion on the expression of the other H1 variant 
proteins 
Although it was difficult to detect the individual H1 variant proteins by TAU 
and RP-HPLC under the analysis conditions employed here, isolated H1 variant 
proteins were partially separated by 18% SDS-PAGE. Three major bands were 
detected in both control and H1.4 knockdown cells. The intensity of band 1 in 
Figure 4-2D was decreased in H1.4 knockdown cells, suggesting that this band 
may include the H1.4 protein. On the other hand, the intensity of band 3 shown in 
Figure 4-2D was increased in H1.4 knockdown cells, suggesting that this band 
may include the H1.0 protein. Although I could not determine the identity of H1 
variants, these results indicate that H1.4 depletion increases the other H1 variant 
proteins. I will improve the separation method of H1 variant proteins, and clarify 
which H1 variant proteins are increased by H1.4 depletion in future.   
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4-4. Discussion 
Previous studies showed that when H1 is decreased by some reason, cells 
try to compensate and keep the stable amount of H1. In this study, I found that 
H1.4 depletion resulted in the increased expression of H1.0 and H1.2 mRNA, 
while H1.0 depletion resulted in the increased expression of H1.X mRNA. These 
results suggest that the compensation of the amount of H1 is regulated before 
translation. However, it is still unclear how H1 depletion is sensed and regulated 
at mRNA level. The function of H1 is to construct the higher order chromatin 
structure. Therefore, H1 is thought to be transcriptional repressor. It is possible 
that H1 regulates the gene expression of other H1 variant genes. There are two 
ideas; first one is that H1.4 binds to the regulatory region of H1.0 gene, and when 
H1.4 is reduced, down-regulated H1.0 gene is expressed, second one is that H1.4 
binds to the regulatory region of high-mobility group box 1 (HBP1) transcription 
factor [82], which is a specific transcriptional regulator of H1.0 gene, and when 
H1.4 is reduced, HBP1 is expressed, which leads to the expression of H1.0 gene. 
To demonstrate these ideas, next I would like to examine whether H1.4 binds to 
the regulatory region of H1.0 gene or HBP1 gene by chromatin 
immunoprecipitation assay.  
H1 variants are differentially expressed and incorporated into chromatin 
during differentiation [62]. It has been shown that the expression of H1.0 and H1.X 
genes was increased, whereas the expression of H1.2, H1.3, H1.4, and H1.5 
genes were clearly down-regulated during the retinoic acid (RA)-induced 
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differentiation of NT2 cells [62]. It has a possibility that the expression of H1 
variant genes upon differentiation is regulated by a same mechanism maintaining 
the amount of H1. 
Linker histone H1 is an essential component constructing the chromatin 
structure. H1 depletion changes the nucleosome spacing and chromatin 
compaction [81]. Therefore, cells have a back-up system keeping stable amount 
of H1, which contributes to the maintenance of chromatin structure. Chromatin 
structure is involved in the regulation of gene expression. Thus, this study 
contributes to the understanding of mechanism by which gene expression is 
properly regulated. 
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4-5. Figures and legends 
 
 
 
 
Figure 4-1. The effect of H1.4 or H1.0 depletion on the expression of the 
other H1 variant genes. 
(A) The effect of H1.4 depletion on the expression of the other H1 variant genes. 
RNA was extracted from HCT116 cell lines stably expressing control luciferase 
shRNA or H1.4 shRNA. RT-qPCR was performed using gene-specific primers. 
White and black bars indicate the results from control and either H1.4 or H1.0 
shRNA, respectively. Relative mRNA levels were normalized by the expression 
level of GAPDH. The expression of H1.1, H1.3, and H1.5 mRNA was not detected 
in both control and H1 knockdown HCT116 cell lines. (B) The effect of H1.0 
depletion on the expression of the other H1 variant genes. RNA extraction and 
RT-qPCR was performed as described in (A). 
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Figure 4-2. Separation of H1 variant proteins. 
(A) Isolation of H1 protein by acid extraction. Cells were homogenized with a 
homogenized buffer. Crude nuclei were collected and re-suspended in high salt 
buffer. To isolate all histone proteins, crude chromatin was re-suspended in cold 
0.2 M H2SO4. Supernatant was precipitated with 35% TCA. Histone pellet was 
washed by acetone. To isolate H1 protein, crude chromatin was re-suspended in 
5% HClO4. Supernatant was precipitated with acetone containing 10 mM HCl. H1 
pellet was washed by cold acetone. (B) TAU gel. H1 protein (Lane 1) and total 
histone proteins (Lane 2) extracted from HeLa cells were separated by triton acid 
urea (TAU) gel and visualized by CBB staining. 
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Figure 4-2. Separation of H1 variant proteins. 
(C) Reverse phase high performance liquid chromatography (RP-HPLC). Histone 
sample was run using standard C-18 column with an acetonitrile gradient. Buffer 
A and B are composed of 0.1% acetic acid and 95% acetonitrile in 0.1% acetic 
acid, respectively. The peaks indicated by arrowheads were collected and further 
analyzed by mass-spectrometry. 
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Figure 4-2. Separation of H1 variant proteins. 
(D) Identification of histone composition of individual HPLC fractions by SDS-18% 
PAGE. The fractionated samples derived from RP-HPLC were separated by 18% 
SDS-PAGE and visualized by CBB staining. The Reverse phase high 
performance liquid chromatography (RP-HPLC). The fractionated time was shown 
above. The samples were analyzed by mass-spectrometry. Identified histones 
were shown above. Recombinant histone proteins were shown in lane 13 to 17. 
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Figure 4-3. The effect of H1.4 depletion on the expression of other H1 
variant proteins. 
(A) SDS-PAGE. H1 proteins, which are Isolated from HCT116 cell lines stably 
expressing control luciferase shRNA and H1.4 shRNA, were separated by 18% 
SDS-PAGE. Lane 1 and 2 in left panel showed the control and H1.4 knockdown 
cells, respectively. (B) Enlarged image of the protein bands of H1 were shown. 
Three major bands were observed (Lane 1 to 3). The band intensity was 
measured and shown in the Figure below.  
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4-6. Table for primers 
Primers used for RT-PCR 
Primers Sequences 
H1.2-F TGCCAAAAGTGCTGCTAAGG 
H1.2-R GGTTTTAGAAGTAGGCGTTCGC 
H1.4-F CGAATTGCTCTCGCTCAC 
H1.4-R CCTTCTTCTTCACGGGAGTC 
H1.0-F ATGCTCACCACCACCTTTTG 
H1.0-R TGTTGCTGTCCTTGCACAAC 
H1.X-F CCCAACGATGTAGCGTTTTT 
H1.X-R AAGGCCGAGAGCCAATAGA 
GAPDH-F CCACATCGCTCAGACACCAT 
GAPDH-R GCGCCCAATACGACCAAA 
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Chapter 5: Summary 
In chapter 1, the various biological functions of NPM1 are described. In this 
dissertation, I focused on the function of NPM1 in the transcriptional regulation of 
the genes, especially the IFN-γ induced genes as described in Chapter 2. 
Although we previously reported the function of NPM1 as a chromatin remodeling 
factor, the transcriptional regulatory function of NPM1 was distinct from the 
chromatin regulatory functions of NPM1. I demonstrated that NPM1 depletion 
selectively decreases the transcription of IFN-γ induced genes, suggesting that 
NPM1 positively regulates these gene expressions. I showed that NPM1 directly 
binds to STAT1 and regulates the expression of the reporter gene containing GAS. 
NPM1 knockdown decreases the transcriptional activity of the CIITA pIV promoter. 
Although the CIITA pIV promoter contains the STAT1 binding site, NPM1 did not 
strongly affect the STAT1 function on the CIITA pIV. The effect of NPM1 was 
cancelled when the IRF1 binding site was deleted or mutated. Thus, it is likely that 
NPM1 regulates the expression of CIITA through IRF1. Consistent with previous 
studies, I found that NPM1 shows potential ability to associate with IRF1. Further 
study is required to clarify the molecular mechanism regulating the function of 
STAT1 and IRF1 by NPM1.  
In chapter 3, I biochemically characterized the seven somatic H1 variants. I 
showed that the cellular mobility of H1 variants was different and classified into 
three groups, those with fast (H1.X), intermediate (H1.1 and H1.2), and slow 
group (H1.3, H1.4, H1.5, and H1.0). Since the cellular mobility of H1 reflects its 
 85 
intrinsic DNA, nucleosome and chaperone binding activities, I examined the 
difference of these binding activities among H1 variants. I found that H1.X shows 
a lower DNA, nucleosome, and histone chaperone binding activities. This is 
probably the reason why H1.X has the highest cellular mobility. Furthermore, I 
showed that previously known histone chaperones directly interact with H1 variant 
proteins. The histone chaperones, TAF-I and B23, which also associate with H1 in 
vivo, showed the distinct chaperone activity toward H1.  
In chapter 4, I focused on the regulation mechanism maintaining the amount 
of H1. To investigate whether the H1 depletion increases the mRNA expression of 
the other H1 variants genes, I established either H1.4 or H1.0 knockdown cell 
lines. I demonstrated that H1.4 depletion resulted in increased expression of H1.0 
and H1.2 mRNA, while H1.0 depletion resulted in increased expression of H1.X 
mRNA. Although the expression of H1.0 and H1.2 mRNA was increased by H1.4 
depletion, I wanted to check whether the protein expression level of H1.0 was also 
increased by H1.4 depletion. Since there are no commercially available antibodies 
against individual H1 variants, I tried to analyze H1 variant proteins by learning 
the method of TAU gel and RP-HPLC. However, TAU gel was not suitable for 
separating the H1 variant proteins, while RP-HPLC partially separated the H1 
variant proteins. By improving the analysis condition of RP-HPLC, I will separate 
the individual H1 variant proteins.  
Even though I could not confirm that the protein level of H1.0 was increased 
by H1.4 depletion, the result of SDS-PAGE suggested that H1.4 depletion 
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increased the other H1 variant proteins.   
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Chapter 6: Significance and perspective 
I demonstrated that NPM1 has dual functions for the regulation of gene 
expression. Firstly, NPM1 acts as a histone chaperon and promotes the 
chromatin remodeling, which allows the efficient gene expression. Secondly, 
NPM1 acts as a transcriptional co-regulator and enhances the activity of 
transcription factors by their direct interaction, which promotes the gene 
expression.  
In addition, it was previously revealed that NFκB requires the NPM1 as a 
cofactor for the maximal expression of its target genes. It was suggested that two 
oncogenic factors, NPM1 and NFκB cooperatively regulate the expression of 
inflammatory genes. Interestingly, it was reported that the up-regulation of STAT1 
activity correlates with the tumor progression. Therefore, it is possible that 
increased expression of NPM1 in tumor cells contributes to the tumor 
microenvironment by enhancing the activity of NFκB, STAT1, and IRF1. This may 
support the function of NPM1 as an oncogene. In the future, it is possible that the 
therapeutic drug inhibiting their interaction can suppress the tumor progression 
and invasion. Because my study suggests that NPM1 positively regulates the 
expression of IFN-γ induced genes, which plays critical roles in both acquired and 
innate immune system, NPM1 can possibly enhance the immune reaction during 
infections.  
Since chromatin structure is closely related to the regulation of gene 
expression, I examined how chromatin structure is regulated and maintained. To 
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this end, I focused on the linker histone H1, which is one of the components of 
chromatin structure. I demonstrated the distinct DNA, nucleosome, and histone 
chaperone binding activities of H1 variants. It is possible that these distinct 
characteristics are important to make a variety of chromatin conformation and 
thereby gene expression. In the future, it is also interesting that the DNA binding 
activity of H1 is affected by its post-transcriptional modification and DNA 
methylation.  
So far, it is suggested that cells can quickly sense decreased of H1 using the 
backup system to maintain the chromatin structure and the proper gene 
expression. I demonstrated that H1.4 depletion resulted in the increased 
expression of H1.0 and H1.2 mRNA, suggesting that this backup system is 
regulated before translation. However, the mechanism is still unclear. It is 
hypothesized that H1.4 normally inhibits the transcription of H1.0 gene or HBP1 
gene, which encodes a transcription factor to stimulate the H1.0 gene. Therefore, 
it will be interesting to examine whether H1.4 exists in the regulatory region of 
H1.0 gene or HBP1 gene. The expression of S-phase dependent H1 variant 
genes is decreased during differentiation, however, the expression of S-phase 
independent H1 variant genes is increased, suggesting that the amount of H1 is 
sensed and regulated by the backup system during differentiation.  
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